title: Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France.
abstract: OBJECTIVE
  To evaluate the cervical cancer (CC) reduction at individual and population level following different prevention strategies (age-specific vaccination and/or screening) in France.
  
  
  METHODS
  A lifetime Markov model was constructed with 11 health states covering the progression from human papillomavirus (HPV) infection to the development of precancerous lesions, CC and death. A screening module took into account the effects of detection and early treatment. Cohorts of girls were entered into the model at age 11 years; the model was run for 95 years using one-year cycles.
  
  
  RESULTS
  Vaccination combined with screening substantially reduced the incidence of precancerous lesions and CC compared with screening alone. Vaccination was beneficial regardless of age at vaccination, but the greatest benefit was obtained with an early vaccination. The clinical results were the best for vaccination at 11-13 years when lifetime horizon was considered, and for vaccination at 15-17 years for shorter observation period.
  
  
  CONCLUSIONS
  The model results indicate that HPV vaccination offers additional protection against CC when combined with screening. The optimum starting age for vaccination varies depending on the observation period duration.
authors.affiliation: Laboratoires GlaxoSmithKline, Marly-le-Roi, France.
authors.forename: Abdelkader
authors.initials: A
authors.lastname: El Hasnaoui
authors.forename: Nadia
authors.initials: N
authors.lastname: Demarteau
authors.forename: Denis
authors.initials: D
authors.lastname: Granados
authors.forename: Baudouin
authors.initials: B
authors.lastname: Standaert
authors.forename: Bruno
authors.initials: B
authors.lastname: Detournay
mesh_terms: D000293:Adolescent; D002648:Child; D015331:Cohort Studies; D005260:Female; D005602:France; D006801:Humans; D008390:Markov Chains; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D011634:Public Health; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*
chemical_list: D053918:Papillomavirus Vaccines